Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State
Odds of cardiac arrest were higher in hospitalized COVID-19 patients in New York City who received Azithromycin+Hydroxychloroquine compared to patients who received one or neither drug. Among a random sample of 1438 hospitalized, laboratory-confirmed COVID-19 cases across metropolitan New York City, “compared with patients receiving neither drug, cardiac arrest was significantly more likely in patients receiving hydroxychloroquine + azithromycin (adjusted OR, 2.13 [95% CI, 1.12-4.05]), but not hydroxychloroquine alone (adjusted OR, 1.91 [95% CI, 0.96-3.81]) or azithromycin alone (adjusted OR, 0.64 [95% CI, 0.27-1.56]).”
0
1
Contributors are:
Who are from:
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Hazard ratio for time to in-hospital mortality amongst hospitalized COVID-19 patients in New York City were not significantly different for those given Azithromycin, Hydroxychloroquine, or a combination
Proportion of abnormal ECG findings in hospitalized COVID-19 patients in New York City were higher amongst those who received Azithromycin+Hydroxychloroquine and Hydroxychloroquine
Hazard ratios for ventricular arrhythmia among COVID-19 patients given different antimalarial and macrolide therapies from multinational registry of patients hospitalized between 12/20/19 and 4/14/20
Hazard ratios for in-hospital mortality among COVID-19 patients given different antimalarial and macrolide therapies from multinational registry of patients hospitalized between 12/20/19 and 4/14/20
Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State
Findings from a Systematic Review and Meta-Analysis on the Effect of Hydroxychloroquine With or Without Azithromycin on the Mortality of COVID-19 Patients
Hazard ratio for time to in-hospital mortality amongst hospitalized COVID-19 patients in New York City were not significantly different for those given Azithromycin, Hydroxychloroquine, or a combination
Proportion of abnormal ECG findings in hospitalized COVID-19 patients in New York City were higher amongst those who received Azithromycin+Hydroxychloroquine and Hydroxychloroquine
Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State
A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19
Hydroxychloroquine as Prophylactic Treatment for COVID-19
Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial
Observational Study of Hydroxychloroquine in Hospitalized Patients with COVID-19
Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State
Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis
Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial
Learn After
Methods for determining odds of cardiac arrest amongst hospitalized COVID-19 patients in New York City given Azithromycin, Hydroxychloroquine, or a combination
Hazard ratio for time to in-hospital mortality amongst hospitalized COVID-19 patients in New York City were not significantly different for those given Azithromycin, Hydroxychloroquine, or a combination
Proportion of abnormal ECG findings in hospitalized COVID-19 patients in New York City were higher amongst those who received Azithromycin+Hydroxychloroquine and Hydroxychloroquine